If you have a Facebook account we strongly recommend you to BioMedReports.com is the news portal which covers Wall Street's biomedical sector and delivers financial and investment intelligence to a community of highly informed investors has Healthcare stock news and updates to its calendar ...

guest published in:05-03   reply:0   view:5    last updated:05-03 07:29( guest )

Stephen M. Simes BioSante's president & chief executive officer will speak at 1:45 pm EDT and will provide an overview of BioSante's portfolio of cancer vaccines currently in multiple Phase II clinical trials. The conference will be hosted by MD Becker Partners and sponsored by JMP Securities ...

guest published in:10-29   reply:0   view:43    last updated:10-29 20:30( guest )

BioSante's (NASDAQ: BPAX) stock has built a significant retail investor following as well as over 40% institutional ownership and has had extensive media coverage as its key product LibiGel ® gets closer to market as the first FDA-approved drug for female sexual dysfunction. The followin ...

guest published in:10-01   reply:0   view:21    last updated:10-01 11:29( guest )

BioSante's lead products include LibiGel (transdermal testosterone gel) for the treatment of female sexual dysfunction (FSD) which is in Phase III clinical development under a U.S. Food and Drug Administration (FDA) Special Protocol ...

guest published in:05-23   reply:0   view:45    last updated:05-23 14:47( guest )

BioSante reported that with 2869 women enrolled and over 3000 women-years of exposure in its LibiGel Phase III cardiovascular and breast cancer safety study there have been 17 adjudicated cardiovascular (CV) events with a lower than anticipated event rate of approximately 0.57 percent. There h ...

guest published in:03-15   reply:0   view:26    last updated:03-15 16:26( guest )

author:admin    comment:0   view:3   userful 1

BioSante Pharmaceuticals Inc. today reported on its financial results for the first quarter of 2012 and cash balance as of March 31 2012.

author:admin    comment:0   view:5   userful 1

When the shares of BioSante Pharmaceuticals (BPAX) fell last December following the failure of its sexual dysfunction drug LibiGel in two late-stage clinical trials questions swirled about the company's ...

author:admin    comment:0   view:9   userful 1

BioSante Pharmaceuticals Inc. today announced that Stephen M. Simes BioSante s president & CEO will present a corporate update at the Roth Health Care Conferen

author:admin    comment:0   view:17   userful 1

(Reuters) - U.S. drug regulators approved a new testosterone gel from BioSante Pharmaceutical Inc and Teva Pharmaceuticals a Food and Drug Administration spokeswoman said. Bio-T-Gel is a topical once-a-day gel absorbed by the skin to treat low testosterone levels in men a condition known as hyp ...

author:admin    comment:0   view:10   userful 1

BioSante Pharmaceuticals Inc. today announced that Stephen M. Simes BioSante s president & CEO will present a corporate update at the BIO CEO & Investor Co